The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase 3 trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell lymphomas (MTCL).
Owen A. O'Connor
Consultant or Advisory Role - Seattle Genetics (U); Takeda (U)
Honoraria - Takeda
Research Funding - Seattle Genetics; Takeda
Barbara Pro
Consultant or Advisory Role - Seattle Genetics (U)
Research Funding - Seattle Genetics
Other Remuneration - Seattle Genetics
Tim Illidge
Consultant or Advisory Role - Seattle Genetics (U); Takeda (U)
Honoraria - Takeda
Research Funding - Seattle Genetics
Lorenz H. Trumper
Consultant or Advisory Role - Seattle Genetics (U)
Emily K. Larsen
Employment or Leadership Position - Seattle Genetics
Stock Ownership - Seattle Genetics
Dana A. Kennedy
Employment or Leadership Position - Seattle Genetics
Stock Ownership - Seattle Genetics